First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial

Eichhorst, Barbara; Fink, Anna-Maria; Bahlo, Jasmin; Busch, Raymonde; Kovacs, Gabor; Maurer, Christian; Lange, Elisabeth; Koeppler, Hubert; Kiehl, Michael; Soekler, Martin; Schlag, Rudolf; Vehling-Kaiser, Ursula; Koechling, Georg; Ploeger, Christoph; Gregor, Michael; Plesner, Torben; Trneny, Marek; Fischer, Kirsten; Doehner, Harmut; Kneba, Michael; Wendtner, Clemens-Martin; Klapper, Wolfram; Kreuzer, Karl-Anton; Stilgenbauer, Stephan; Boettcher, Sebastian; Hallek, Michael

First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial

Autor(en):

Eichhorst, Barbara; Fink, Anna-Maria; Bahlo, Jasmin; Busch, Raymonde; Kovacs, Gabor; Maurer, Christian; Lange, Elisabeth; Koeppler, Hubert; Kiehl, Michael; Soekler, Martin; Schlag, Rudolf; Vehling-Kaiser, Ursula; Koechling, Georg; Ploeger, Christoph; Gregor, Michael; Plesner, Torben; Trneny, Marek; Fischer, Kirsten; Doehner, Harmut; Kneba, Michael; Wendtner, Clemens-Martin; Klapper, Wolfram; Kreuzer, Karl-Anton; Stilgenbauer, Stephan; Boettcher, Sebastian; Hallek, Michael

Tübinger Autor(en):

Sökler, Martin

Erschienen in:

Lancet Oncology (2016), Bd. 17, H. 7, S. 928-942

Verlagsangabe:

Elsevier Science Inc

Sprache:

Englisch

Referenz zum Volltext:

http://dx.doi.org/10.1016/S1470-2045(16)30051-1

ISSN:

1474-5488